Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

ESMO Breast Cancer 2024: Industry Sponsored Satellite Symposia

ESMO-Breast-Cancer-2024-1000x250

Click on the links below to access the Industry Sponsored Satellite Symposia Invitations.

Many Patients, Many Needs: Challenging HER2-Expressing Metastatic Breast Cancer Cases

01-Many-Patients-Many-Needs-Challenging-HER2-DAIICHI-SANKYO-ASTRAZENECA-thumb

Wednesday, 11:30-12:30 CEST
View the satellite invitation

The Path to Strategic Sequencing in 3L HER2+ Metastatic Breast Cancer

02-The-Path-to-Strategic-Sequencing-in-3L-HER2-Metastatic-Breast-Cancer-PFIZER-thumb

Wednesday, 11:30-12:30 CEST
View the satellite invitation

Real-World HER2-Positive Early Breast Cancer: Optimising Curative Intent Therapy

03-Real-World-HER2-Positive-Early-Breast-Cancer-Optimising-Curative-Intent-Therapy-MEDSCAPE-thumb

Wednesday, 11:30-12:30 CEST
View the satellite invitation

Tailoring Journeys: Customised Care with CDK4/6 Inhibitors in HR+ HER2- Metastatic Breast Cancer

04-Tailoring-Journeys-Customised-Care-with-CDK4-6-Inhibitors-PFIZER-thumb

Wednesday, 18:30-19:30 CEST
View the satellite invitation

Current and Upcoming Treatment Strategies after CDK4/6 Inhibitors for Patients with ER+/HER2− Advanced Breast Cancer

05-Current-and-Upcoming-Treatment-Strategies-after-CDK4-6-Inhibitors-for-Patients-MENARINI-thumb

Wednesday, 18:30-19:30 CEST
View the satellite invitation

Advances in a Dynamic Disease: A Patient-First Approach to HR-Positive mBC

06-Advances-in-a-Dynamic-Disease-A-Patient-First-Approach-to-HR-Positive-mBC-ASTRAZENECA-thumb

Wednesday, 18:30-19:30 CEST
View the satellite invitation

Addressing Treatment Questions in Early Breast Cancer: A Case-Based Approach

07-Addressing-Treatment-Questions-in-Early-Breast-Cancer-A-Case-Based-Approach-MSD-thumb

Thursday, 12:45-13:45 CEST
View the satellite invitation

Safeguarding Patients with HR+, HER2-, High-Risk Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

08-Safeguarding-Patients-with-HR-HER2-High-Risk-Early-Breast-Cancer-PEERVIEW-thumb

Thursday, 12:45-13:45 CEST
View the satellite invitation

Breaking New Ground with CDK4/6 Inhibitors: Case-Based Discussions on Treatment Decisions in HR+/HER2− Breast Cancer

09-Breaking-New-Ground-with-CDK4-6-Inhibitors-NOVARTIS-thumb

Thursday, 12:45-13:45 CEST
View the satellite invitation

Experts Debate: Navigating the Complexities of Metastatic Breast Cancer Treatment

12-Experts-Debate-Navigating-the-Complexities-of-Metastatic-Breast-Cancer-Treatment-GILEAD-thumb

Thursday, 18:30-19:30 CEST
View the satellite invitation

Advance, Deliver, Challenge: ADCs and the Potential Future of HR Positive mBC

13-Advance-Deliver-Challenge-ADCs-and-the-Potential-Future-of-HR-Positive-mBC-DAIICHI-thumb

Friday, 12:30-13:30 CEST
View the satellite invitation

Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.